Date: 2014-10-01
Type of information: Product acquisition
Compound: Illumina® NextSeq500® sequencer
Company: Hybrigenics (France)
Therapeutic area:
Type agreement: acquisition
Action mechanism:
Disease:
Details: * On October 1, 2014, Hybrigenics, a bio-pharmaceutical company with a focus on research and development of new treatments of proliferative diseases and specialised in proteomic and genomic scientific services, announced the acquisition of an Illumina® NextSeq500® sequencer by Helixio, its division in charge of genomic studies and services. This latest machine from Illumina®, the world leader in next generation sequencing technologies,can sequence the human whole genome or of most plant or animal individual organisms in less than two days. In addition to speed, the flexibility to adapt to the parallel sequencing of the desired number of exomes or transcriptomes with the optimal level of accuracy, is the other important feature of this new equipment. Helixio, Hybrigenics’ genomic division, will take advantage of these properties to deliver customized state-of-the-art sequencing results to its fee-for-service customers from all life sciences. Helixio will also be able to support Hybrigenics’ internal R&D studies with newly available genomic information.
Financial terms:
Latest news:
